via inpharm.com
Projects in phase I will bear the brunt of the cuts, accounting for 15 programmes out of a total of 31 that have either been halted completely or cut back as the company takes a hard look at which drugs will help it manage a number of looming patent expiries.
No comments:
Post a Comment